Literature DB >> 27765344

Measures of disease status in systemic sclerosis: A systematic review.

Tien Tay1, Nava Ferdowsi1, Murray Baron2, Wendy Stevens3, Marie Hudson2, Susanna M Proudman4, Mandana Nikpour5.   

Abstract

OBJECTIVES: To identify and appraise measures of disease status in systemic sclerosis (SSc).
METHODS: A systematic review of Medline (1966-2015), EMBASE (1974-2015), and Cochrane Library (inception-2015) was undertaken to identify indices of disease status in SSc. We focused on objective measures and excluded non-English articles. Measures were reviewed for content, whether they measured activity, damage and/or severity and whether they were validated according to the OMERACT filter.
RESULTS: Of the 4558 articles retrieved through the search, we identified 58 articles for review. We found a further 44 articles through a search of the bibliography of relevant articles. We identified the following 10 "composite" (multi-organ) indices: two disease activity indices, six disease severity scales, and two combined response indices. There was no disease damage index for SSc.
CONCLUSIONS: We identified a number of composite and organ-specific indices in SSc, incorporating mostly objective measures, developed to quantify disease activity, severity, and response in clinical trials. However, none of the indices was developed to exclusively quantify organ damage. Most of the existing indices require further validation according to the OMERACT filter. There is a need to develop and validate a disease damage index in SSc.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Damage index; Disease activity; Outcome measure; Response measure; Severity scale; Systemic sclerosis

Mesh:

Year:  2016        PMID: 27765344     DOI: 10.1016/j.semarthrit.2016.07.010

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  7 in total

1.  The challenges and controversies of measuring disease activity in systemic sclerosis.

Authors:  Laura Ross; Murray Baron; Mandana Nikpour
Journal:  J Scleroderma Relat Disord       Date:  2018-03-27

2.  An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups.

Authors:  Murray Baron; Bashar Kahaleh; Elana J Bernstein; Lorinda Chung; Philip J Clements; Christopher Denton; Robyn T Domsic; Nava Ferdowsi; Ivan Foeldvari; Tracy Frech; Jessica K Gordon; Marie Hudson; Sindhu R Johnson; Dinesh Khanna; Zsuzsannah McMahan; Peter A Merkel; Sonali Narain; Mandana Nikpour; John D Pauling; Laura Ross; Antonia Maria Valenzuela Vergara; Alessandra Vacca
Journal:  J Scleroderma Relat Disord       Date:  2018-07-18

Review 3.  Systemic sclerosis and the gastrointestinal tract.

Authors:  Irena Walecka
Journal:  Prz Gastroenterol       Date:  2017-09-30

4.  Scleroderma Renal Crisis Debute with Thrombotic Microangiopathy: A Successful Case Treated with Eculizumab.

Authors:  Maite Hurtado Uriarte; Carolina Larrarte; Laura Bravo Rey
Journal:  Case Rep Nephrol       Date:  2018-10-23

5.  Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS).

Authors:  Boyang Zheng; Marie Hudson; Mianbo Wang; Murray Baron
Journal:  Arthritis Res Ther       Date:  2020-06-05       Impact factor: 5.156

6.  Validity and reliability of the Patient Health Questionnaire-8 in Swedish for individuals with systemic sclerosis.

Authors:  Malin Mattsson; Gunnel Sandqvist; Roger Hesselstrand; Annica Nordin; Carina Boström
Journal:  Rheumatol Int       Date:  2020-07-13       Impact factor: 2.631

7.  Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition.

Authors:  Clarissa Corinaldesi; Rebecca L Ross; Giuseppina Abignano; Cristina Antinozzi; Francesco Marampon; Luigi di Luigi; Maya H Buch; Valeria Riccieri; Andrea Lenzi; Clara Crescioli; Francesco Del Galdo
Journal:  Int J Mol Sci       Date:  2021-03-12       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.